Received Apr 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U8510AA | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2164395 | OT |
No adverse effects reported; TE for ROTATEQ and VAXELIS; This spontaneous report was received from a consumer referring to a currently 2-month-old patient of unknown gender. The patient's medical history, historical dugs, past drug adverse or allergies were unknown, concurrent conditions, and concomitant drugs were not reported. On an unknown date in 2026, the patient was vaccinated with rotavirus vaccine live, pentavalent (ROTATEQ) vial (lot#: 2164395, expiration date: 22-MAR-2027; dose and strength were not reported) orally for prophylaxis. On an unknown date in 2026, the patient was vaccinated with administered diphtheria toxoid (+) hepatitis B virus vaccine rHBsAg (yeast) (+) Hib conj vaccine (OMPC) (+) pertussis acellular 5-component vaccine (+) poliovirus vaccine inactivated (Vero) (+) tetanus toxoid (V419) injection (0.5 ml, lot#: U8510AA, expiration date: 30-APR-2028; route of administration was not reported). Both vaccines experienced temperature excursion (TE) (product storage error). No adverse effects reported (no adverse event). This case was received from the same reporter with the cases US-009507513-2418484, US-009507513-2418315, and US-009507513-2418432.